APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rx Irritable Bowel Syndrome (IBS) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchRx Irritable Bowel Syndrome (IBS) Drugs Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Rx Irritable Bowel Syndrome (IBS) Drugs Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Rx Irritable Bowel Syndrome (IBS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rx Irritable Bowel Syndrome (IBS) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Rx Irritable Bowel Syndrome (IBS) Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Rx Irritable Bowel Syndrome (IBS) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Rx Irritable Bowel Syndrome (IBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rx Irritable Bowel Syndrome (IBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rx Irritable Bowel Syndrome (IBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Rx Irritable Bowel Syndrome (IBS) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Rx Irritable Bowel Syndrome (IBS) Drugs market include Allergan, Bausch Health, Ironwood Pharmaceuticals, Sebela Pharmaceuticals and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Rx Irritable Bowel Syndrome (IBS) Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rx Irritable Bowel Syndrome (IBS) Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rx Irritable Bowel Syndrome (IBS) Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Rx Irritable Bowel Syndrome (IBS) Drugs market.

Rx Irritable Bowel Syndrome (IBS) Drugs Segment by Company

Allergan

Bausch Health

Ironwood Pharmaceuticals

Sebela Pharmaceuticals

Takeda

Rx Irritable Bowel Syndrome (IBS) Drugs Segment by Type

IBS-D Drugs

IBS-C Drugs

Others

Rx Irritable Bowel Syndrome (IBS) Drugs Segment by Application

Women

Men

Rx Irritable Bowel Syndrome (IBS) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Rx Irritable Bowel Syndrome (IBS) Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Rx Irritable Bowel Syndrome (IBS) Drugs key companies, revenue, market share, and recent developments.

3. To split the Rx Irritable Bowel Syndrome (IBS) Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Rx Irritable Bowel Syndrome (IBS) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Rx Irritable Bowel Syndrome (IBS) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Rx Irritable Bowel Syndrome (IBS) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rx Irritable Bowel Syndrome (IBS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rx Irritable Bowel Syndrome (IBS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rx Irritable Bowel Syndrome (IBS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rx Irritable Bowel Syndrome (IBS) Drugs industry.

Chapter 3: Detailed analysis of Rx Irritable Bowel Syndrome (IBS) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Rx Irritable Bowel Syndrome (IBS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Rx Irritable Bowel Syndrome (IBS) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Rx Irritable Bowel Syndrome (IBS) Drugs Industry Trends Table 2. Rx Irritable Bowel Syndrome (IBS) Drugs Industry Drivers Table 3. Rx Irritable Bowel Syndrome (IBS) Drugs Industry Opportunities and Challenges Table 4. Rx Irritable Bowel Syndrome (IBS) Drugs Industry Restraints Table 5. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Company (2021-2026) Table 7. Global Rx Irritable Bowel Syndrome (IBS) Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Rx Irritable Bowel Syndrome (IBS) Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Rx Irritable Bowel Syndrome (IBS) Drugs Company, Product Type & Application Table 10. Global Rx Irritable Bowel Syndrome (IBS) Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Rx Irritable Bowel Syndrome (IBS) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of IBS-D Drugs Table 15. Significant Companies of IBS-C Drugs Table 16. Significant Companies of Others Table 17. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type (2021-2026) Table 21. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Women Table 23. Significant Companies of Men Table 24. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application (2021-2026) Table 28. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application (2027-2032) Table 29. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Region (2021-2026) Table 32. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Region (2027-2032) Table 34. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Market Share by Country (2027-2032) Table 39. Allergan Company Information Table 40. Allergan Business Overview Table 41. Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 43. Allergan Recent Development Table 44. Bausch Health Company Information Table 45. Bausch Health Business Overview Table 46. Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 48. Bausch Health Recent Development Table 49. Ironwood Pharmaceuticals Company Information Table 50. Ironwood Pharmaceuticals Business Overview Table 51. Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 53. Ironwood Pharmaceuticals Recent Development Table 54. Sebela Pharmaceuticals Company Information Table 55. Sebela Pharmaceuticals Business Overview Table 56. Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 58. Sebela Pharmaceuticals Recent Development Table 59. Takeda Company Information Table 60. Takeda Business Overview Table 61. Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 63. Takeda Recent Development Table 64. Research Programs/Design for This Report Table 65. Authors List of This Report Table 66. Secondary Sources Table 67. Primary Sources List of Figures Figure 1. Rx Irritable Bowel Syndrome (IBS) Drugs Product Image Figure 2. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Rx Irritable Bowel Syndrome (IBS) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. IBS-D Drugs Image Figure 8. IBS-C Drugs Image Figure 9. Others Image Figure 10. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type (2021-2032) Figure 13. Women Image Figure 14. Men Image Figure 15. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application (2021-2032) Figure 18. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • IBS-D Drugs
  • IBS-C Drugs
  • Others
Applications
  • Women
  • Men
Companies covered
  • Allergan
  • Bausch Health
  • Ironwood Pharmaceuticals
  • Sebela Pharmaceuticals
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Rx Irritable Bowel Syndrome (IBS) Drugs Market Dynamics
  1. 2.1 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Trends
  2. 2.2 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Drivers
  3. 2.3 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Opportunities and Challenges
  4. 2.4 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Restraints
3 Rx Irritable Bowel Syndrome (IBS) Drugs Market by Company
  1. 3.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Rx Irritable Bowel Syndrome (IBS) Drugs Company Ranking (2024-2026)
  4. 3.4 Global Rx Irritable Bowel Syndrome (IBS) Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Rx Irritable Bowel Syndrome (IBS) Drugs Company Product Type and Application
  6. 3.6 Global Rx Irritable Bowel Syndrome (IBS) Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Rx Irritable Bowel Syndrome (IBS) Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Rx Irritable Bowel Syndrome (IBS) Drugs Market by Type
  1. 4.1 Rx Irritable Bowel Syndrome (IBS) Drugs Type Introduction
  2. 4.1.1 IBS-D Drugs
  3. 4.1.2 IBS-C Drugs
  4. 4.1.3 Others
  5. 4.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Type
  6. 4.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type (2021-2032)
5 Rx Irritable Bowel Syndrome (IBS) Drugs Market by Application
  1. 5.1 Rx Irritable Bowel Syndrome (IBS) Drugs Application Introduction
  2. 5.1.1 Women
  3. 5.1.2 Men
  4. 5.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Application
  5. 5.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Application (2021-2032)
  7. 5.2.3 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application (2021-2032)
6 Rx Irritable Bowel Syndrome (IBS) Drugs Regional Value Analysis
  1. 6.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Country, 2025 VS 2032
7 Rx Irritable Bowel Syndrome (IBS) Drugs Country-level Value Analysis
  1. 7.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Rx Irritable Bowel Syndrome (IBS) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Bausch Health
  8. 8.2.1 Bausch Health Company Information
  9. 8.2.2 Bausch Health Business Overview
  10. 8.2.3 Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  12. 8.2.5 Bausch Health Recent Developments
  13. 8.3 Ironwood Pharmaceuticals
  14. 8.3.1 Ironwood Pharmaceuticals Company Information
  15. 8.3.2 Ironwood Pharmaceuticals Business Overview
  16. 8.3.3 Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  18. 8.3.5 Ironwood Pharmaceuticals Recent Developments
  19. 8.4 Sebela Pharmaceuticals
  20. 8.4.1 Sebela Pharmaceuticals Company Information
  21. 8.4.2 Sebela Pharmaceuticals Business Overview
  22. 8.4.3 Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  24. 8.4.5 Sebela Pharmaceuticals Recent Developments
  25. 8.5 Takeda
  26. 8.5.1 Takeda Company Information
  27. 8.5.2 Takeda Business Overview
  28. 8.5.3 Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  30. 8.5.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst